Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations
- 17 July 2021
- journal article
- review article
- Published by Elsevier BV in Value in Health
- Vol. 24 (10), 1520-1530
- https://doi.org/10.1016/j.jval.2021.04.1276
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council (1135054, 1136923)
This publication has 26 references indexed in Scilit:
- Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient DataThe Journal of Pain, 2015
- Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to ItalyExpert Review of Pharmacoeconomics & Outcomes Research, 2015
- The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosisHealth Technology Assessment, 2015
- A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost–effectiveness in GermanyExpert Review of Neurotherapeutics, 2013
- Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple SclerosisPharmacoEconomics, 2012
- Sativex® in multiple sclerosis spasticity: a cost–effectiveness modelExpert Review of Pharmacoeconomics & Outcomes Research, 2012
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisEuropean Journal of Neurology, 2011
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosisNeurological Research, 2010
- A web-based tool for adjusting costs to a specific target currency and price yearEvidence & Policy, 2010
- Estimation of the cost of MS in Europe: Extrapolations from a multinational cost studyMultiple Sclerosis Journal, 2007